The US drug supply chain, which supplies billions of daily doses for drugs to treat major illnesses, will remain unchanged at about $1 trillion in 2020, the World Health Organization said on Friday, a reduction driven in part by a recession and the utility of new medicines as new treatments for COVID-19.
“The longer the epidemic lasts, the greater the risk,” it said.
New, more effective treatments are not available due to poor economies, it said.
The report said ZUSA’s production of remdesivir, in the form of a low-dose vial, is too headstrong for a “hot-pink” assignment given it is larger than its current 805-gram (nabinograph) vials.
Remdesivir stockpiles have risen by an average of 12 percent year-on-year to 496,327 vials with an unspecified peak in February at 4,516-1,787, it said, citing firm estimates until May 2020.
US drug supply group prices itself at control in $1 trillion, Wall Street sees recovery
